About Convergent Therapeutics
Convergent Therapeutics is a private company based in Cambridge, Massachusetts, incorporated in 2020 in Delaware. It has reported $51,392,924 raised in two offerings on Form D since May 2023. Its chief executive is Philip Kantoff.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 2024 | Aug 13, 2024 | $22,222,220of $39.9M target | 1 | $22.2M | EquityRule 506(b) | Form D ↗ |
| Apr 27, 2023 | May 22, 2023 | $29,170,704of $99.1M target | 15 | $1.9M | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $51,392,924 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Convergent Therapeutics's Form D filed Aug 13, 2024.
ES
Eric Sullivan
Executive officer
JS
Jake Simson
Director
Tal Zaks
Director
Also an executive chairman of the board at Averna Therapeutics and a director at Curevo.
JT
Jim Trenkle
Director
PK
Philip Kantoff
CEO and director
AB
Alexander Brown
Executive officer
NB
Neil Bander
Executive officer and director